Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066423
Filing Date
2025-05-08
Accepted
2025-05-08 08:07:16
Documents
53
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rapt-20250331.htm   iXBRL 10-Q 1778658
2 EX-10.1 rapt-ex10_1.htm EX-10.1 248211
3 EX-10.2 rapt-ex10_2.htm EX-10.2 106992
4 EX-10.3 rapt-ex10_3.htm EX-10.3 83613
5 EX-31.1 rapt-ex31_1.htm EX-31.1 18625
6 EX-31.2 rapt-ex31_2.htm EX-31.2 18650
7 EX-32.1 rapt-ex32_1.htm EX-32.1 20334
  Complete submission text file 0000950170-25-066423.txt   6633757

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rapt-20250331.xsd EX-101.SCH 754793
55 EXTRACTED XBRL INSTANCE DOCUMENT rapt-20250331_htm.xml XML 964584
Mailing Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 561 ECCLES AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 489-9000
RAPT Therapeutics, Inc. (Filer) CIK: 0001673772 (see all company filings)

EIN.: 473313701 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38997 | Film No.: 25923991
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)